Pasar al contenido principal

Chemogenetic approaches to study the loss of control over food intake

FJC2019-041020-I

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Formación
Convocatoria Juan de la Cierva Formación
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSITAT POMPEU FABRA CCT

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo preliminar (WorkingPaper)

Unique pharmacodynamic properties and low abuse liability of the μ-opioid receptor ligand (S)-methadone

  • Michaelides, Michael|||0000-0003-0398-4917
  • Levinstein, Marjorie|||0000-0003-4360-1503
  • De Oliveira, Paulo
  • Casajuana-Martin, Nil|||0000-0002-9007-274X
  • Quiroz, Cesar
  • Budinich, Reece
  • Rais, Rana
  • Rea, William
  • Ventriglia, Emilya
  • Llopart, Natàlia
  • Casadó-Anguera, Verònica|||0000-0001-8532-2954
  • Moreno, Estefanía|||0000-0002-2491-5753
  • Walther, Donna
  • Glatfelter, Grant
  • Weinshenker, David|||0000-0002-3678-6215
  • Zarate, Carlos
  • Casadó, Vicent|||0000-0002-1764-3825
  • Baumann, Michael
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
  • Ferré, Sergi|||0000-0002-1747-1779
(R,S)-methadone ((R,S)-MTD) is a racemic μ-opioid receptor (MOR) agonist comprised of (R)-MTD and (S)-MTD enantiomers used for the treatment of opioid use disorder (OUD) and pain. (R)-MTD is used as an OUD treatment, has high MOR potency, and is believed to mediate (R,S)-MTD's therapeutic efficacy. (S)-MTD is in clinical development as an antidepressant and is considered an N-methyl-D-aspartate receptor (NMDAR) antagonist. In opposition to this purported mechanism of action, we found that (S)-MTD does not occupy NMDARs in vivo in rats. Instead, (S)-MTD produced MOR occupancy and induced analgesia with similar efficacy as (R)-MTD. Unlike (R)-MTD, (S)-MTD was not self-administered and failed to increase locomotion or extracellular dopamine levels indicating low abuse liability. Moreover, (S)-MTD antagonized the effects of (R)-MTD in vivo and exhibited unique pharmacodynamic properties, distinct from those of (R)-MTD. Specifically, (S)-MTD acted as a MOR partial agonist with a specific loss of efficacy at the MOR-galanin 1 receptor (Gal1R) heteromer, a key mediator of the dopaminergic effects of opioids. In sum, we report novel and unique pharmacodynamic properties of (S)-MTD that are relevant to its potential mechanism of action and therapeutic use, as well as those of (R,S)-MTD.